Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Anika Therapeutics Inc ANIK

Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.


NDAQ:ANIK - Post by User

Bullboard Posts
Post by wwwallstocktalkcomon Aug 24, 2001 1:45pm
213 Views
Post# 4131363

Approved for use in the United States

Approved for use in the United States When will approval of ORTHOVISC be completed? A highly purified, high molecular weight, high viscosity injectable form of hyaluronic acid (HA) intended to relieve pain and to improve joint mobility and range of motion in patients suffering from osteoarthritis (OA) of the knee. Currently, ORTHOVISC, a brand of sodium hyaluronate is not approved for use in the United States, but it is marketed and sold in Canada, Europe and other countries. ORTHOVISC is a localized injectable treatment for osteoarthritis of the knee which is an alternative to other injectable or oral treatments. ORTHOVISC is injected into the knee to restore the elasticity and viscosity of the synovial fluid.
Bullboard Posts